...
首页> 外文期刊>Journal of neurosurgery. >Thirty years' experience with Gamma Knife surgery for metastases to the brain.
【24h】

Thirty years' experience with Gamma Knife surgery for metastases to the brain.

机译:在伽玛刀外科手术中有30年的经验,可以转移到大脑。

获取原文
获取原文并翻译 | 示例

摘要

OBJECT: The aim of this study was to analyze factors influencing survival time and patterns of distant recurrences after Gamma Knife surgery (GKS) for metastases to the brain. METHODS: Information was available for 1855 of 1921 patients who underwent GKS for single or multiple cerebral metastases at 4 different institutions during different time periods between 1975 and 2007. The total number of Gamma Knife treatments administered was 2448, an average of 1.32 treatments per patient. The median survival time was analyzed, related to patient and treatment parameters, and compared with published data following conventional fractionated whole-brain irradiation. RESULTS: Twenty-five patients survived for longer than 10 years after GKS, and 23 are still alive. Age and primary tumor control were strongly related to survival time. Patients with single metastases had a longer survival than those with multiple metastases, but there was no difference in survival between patients with single and multiple metastases who had controlled primary disease. There were no significant differences in median survival time between patients with 2, 3-4, 5-8, or >8 metastases. The 5-year survival rate was 6% for the whole patient population, and 9% for patients with controlled primary disease. New hematogenous spread was a more significant problem than micrometastases in patients with longer survival. CONCLUSIONS: Patient age and primary tumor control are more important factors in predicting median survival time than number of metastases to the brain. Long-term survivors are more common than previously assumed.
机译:目的:本研究的目的是分析影响伽玛刀手术(GKS)后转移至大脑的生存时间和远处复发方式的因素。方法:在1975年至2007年的不同时间段内,在4个不同的机构中对1921例因单发或多发性脑转移进行GKS手术的患者中的1855名患者提供了信息。伽玛刀治疗的总数为2448例,平均每例患者1.32例治疗。分析了中位生存时间,与患者和治疗参数有关,并与常规分级全脑照射后的公布数据进行了比较。结果:25例患者在GKS后存活超过10年,还有23例还活着。年龄和原发肿瘤控制与生存时间密切相关。具有单一转移的患者比具有多个转移的患者具有更长的生存期,但是具有控制原发性疾病的具有单一转移和多个转移的患者之间的生存期没有差异。在有2、3-4、5-8或> 8转移的患者之间,中位生存时间无显着差异。整个患者群体的5年生存率分别为6%和原发性疾病控制患者的9%。在生存期较长的患者中,新的血源性扩散比微转移更为严重。结论:患者年龄和原发肿瘤控制是预测中位生存时间的重要因素,而不是转移到大脑的数目。长期幸存者比以前假定的更为普遍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号